Rate Video

ESMO 2022 | Challenges of desmoid tumors

Robin Jones • 1 Nov 2022

Robin Jones, MBBS, MRCP, MD, The Royal Marsden NHS Foundation Trust, London, UK, explains desmoid tumors and discusses the main challenges involved in treating them, including their rarity, unpredictability, and the effects on patient quality of life. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

The significance of interactive and educational meetings for sarcoma

Robin Jones • 9 Feb 2022

ANNOUNCE: doxorubicin + olaratumab in advanced soft tissue sarcomas

Robin Jones • 28 Apr 2020

Highlights from ESMO Sarcoma & GIST 2022

Robin Jones • 9 Feb 2022

The latest developments in neo-adjuvant therapy for retroperitoneal sarcoma

Robin Jones • 13 Apr 2022

Related Videos

Trabectedin and pazopanib: an indirect comparison of their ability to treat LMS

How has the trabectedin extended access program benefited sarcoma patients?

The current state of drug development against sarcomas

Response rates to immunotherapy in sarcoma patients and implications for future therapies

Gary Schwartz • 3 Jun 2016